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Immunotherapy against drugs of abuse
Current treatments for drug addiction involve classical pharmacological therapy, involving
the use of competitive or noncompetitive agonists (full, partial, or inverse) and antagonists. Drugs
of abuse enter the brain after crossing the blood-brain barrier rapidly and binding to the proper
receptor(s). They are able to do so because they are small and lipid soluble, and produce reinforcing
effects by increasing levels of dopamine in brain areas associated with reward. This occurs in
specific systems associated with addiction. In the mesolimbic system, neuron cell bodies originate
in the ventral tegmental area (VTA) and project to the nucleus accumbens (NAc), amygdala,
hippocampus, and prefrontal cortex. Dopamine is subsequently released, which contributes to the
development of addiction. Illicit drug use has cost over $11 billion in health care and $193 billion
overall in the United States. Heroin, cocaine, and prescription opioid abuse has become more
prevalent in recent years, causing over 6,000 deaths in the U.S. annually (NIDA 2015). Recent
literature has begun to conceptualize drugs of abuse as toxins, which has led to new approaches in
drug research for the treatment of substance abuse.
One of these approaches is immunotherapy, which integrates vaccination of a drug target
and incorporates the body’s adaptive immune system as a defense against drugs of abuse. The
adaptive immune response is a mechanism of the immune system that is divided into two parts:
humoral and cell-mediated immunity. Humoral immunity refers to the circulation of antibodies in
the blood to find foreign invaders and free molecules that evoke immune response, known as
antigens. Cell-mediated immunity engages T-lymphocytes to recognize antigens and designate
infected cells. Antigen presenting cells (APCs) are phagocytic cells that break down antigens into
smaller molecules and present them on their cell surface. APCs migrate to lymphatic tissue, which
include B cells and T cells. T cells link to the antigen presented on the APC and become activated.
This interaction provokes B cells to generate plasma cells that can create specific antibodies and
immunological memory (Slonczewski and Foster 2014).
Immunotherapy against drugs of abuse is different from conventional vaccinations against
infectious diseases in a few fundamental ways. As stated in the most recent 2005 U.S. patent, the
vaccine is directed against a drug molecule, not an infectious particle. Unlike most vaccines, the
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primary objective of immunization against addictive drugs is therapeutic, not preventative.
However, some clinical objectives regard drug vaccines as practical for prophylactic use,
especially in at-risk populations such as adolescents or the fetuses of drug-addicted pregnant
mothers. The antigen against which drug vaccines are directed is not itself antigenic, and therefore
must be bound to a carrier protein that evokes immune response. Since psychoactive drugs exert
their effects when bound to receptors in the brain, they are effectively inactivated due to antibody
binding in the periphery. If drug is taken when antibodies are present, the antibodies bind to the
drug and prevent its psychoactive and physiological effects (U.S. Patent No. 6,699,474B1). This
method of treatment is relatively new and rapidly developing. Its contributions thus far appear
promising to aid in breaking the cycle of addiction. By preventing drugs of abuse from entering
the central nervous system (CNS), the efficacy of drug effect is reduced.
Conventional treatments with agonists and antagonists are considered “small-molecule
pharmacotherapies.” However, there are risks to substitution therapy, such as methadone, which
is used to treat opiate addiction but may become addictive as an unintended consequence (U.S.
Patent No. 6,699,474B1). Immunopharmacotherapy is effective because it blocks the effects of
drugs peripherally before they can act centrally (Kosten and Owens 2005) by provoking an
endogenous immune response external to the central nervous system, eliminating the concern of
neurotoxicity. Neurotoxicity is a consideration in some pharmacological alternatives for the
treatment of drug addiction. Antibodies isolate drug molecules in the circulating periphery so that
they are designated for neutralization by the immune system.
The 2005 U.S. patent is a continuation of previously filed patents, the earliest dating back
to 1991. It states its objections of drug vaccinations by setting primary endpoints for preclinical
studies. Antibodies are large molecules (150 kDa) so they cannot cross the blood brain barrier,
therefore preventing entry of a drug molecule once it is bound to the antibody (Kosten and Owens
2005). This document reported intentions to increase immunogenicity of previously manufactured
drug vaccines by linkage to a carrier protein to improve efficacy against drugs of physical and
psychological abuse. Immunotherapies are meant to be applied therapeutically as well as
prophylactically, with specificity to one of many abused drugs. The vaccine is prepared by
combining an immunogen, such as the drug target bound covalently and ionically to a carrier
protein, forming a complex referred to as a hapten. The protein-conjugate is often an immunogenic
protein, for example, inactivated cholera toxin is often used as the foreign carrier protein (Kosten

Raimondi, 2

and Owens 2005). The hapten complex is purified by dialysis or chromatography, and then
dissolved in physiological solution for injection preparation. This is referred to as active
immunization. Adjuvants may also be added to enhance the efficiency of the vaccine, increasing
levels of high-quality antibodies in response to immunization. They also enhance the ability of
antibodies to destroy the drug target. The addition of adjuvants is significant because clinical trials
investigating safety and efficacy of immunotherapy vaccines for abused drugs have reported oneto two-thirds of patients failing to achieve a sufficient antibody response likely do to
pharmacogenomics and immune variability. Adjuvants are useful additions to the hapten complex
model of vaccination against drugs of abuse since they defend antigen degradation by interstitial
fluids, display conformational specificity of the immunogenic complex, and aid in other
enhancements of adaptive immune response (Alving et al. 2014). Other kinds of immunotherapy,
referred to as passive, involve the introduction of exogenous antibodies produced in another
animal, isolated in cell culture and already established as specific to the substance abuse target.
These antibodies are often generated from multiple cell lines (Shorter and Kosten 2011).
The effectiveness of immunotherapy vaccines depends on the concentration of antibodies,
and is greatest when antibody-to-drug ratio is highest (Pravetoni et al. 2012). Therefore, threshold
levels of anti-drug antibodies are required to have an effective immune response. In other words,
it is ideal to have maximal concentration and binding affinity in order for immunotherapy to be as
effective as possible (Shorter and Kosten 2011). Immune responses are not usually generated
against molecules smaller than 10 kDa, which is why antibodies are not normally produced for
drugs of abuse, requiring protein conjugation and addition of adjuvant agents in vaccination
delivery systems.
Drug metabolites may be used as haptens instead of addictive drug targets since some drugs
are rapidly metabolized after absorption but before distribution and delivery to the central nervous
system. For example, morphine is rapidly converted into morphine-3-glucoronate and morphine6-glucoronate (U.S. Patent No. 6,699,474B1). Therefore, targeting the active metabolites of some
abused drugs is more effective because they may be present in greater concentrations postabsorption compared to the drug molecule in original form (Kosten and Owens 2005). Two
fundamental mechanisms are responsible for the efficacy of immunotherapy to prevent drug action
in the brain. One mechanism concerns the binding affinity and specificity of antibodies to
immunotherapeutic drug targets to prevent central action. As previously mentioned, increased
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concentrations of high quality antibodies that bind with high affinity to a drug or its metabolites is
key to the efficacy of this treatment. The second mechanism is slowing the rate of entry of free
(unbound) drug molecules in plasma across the blood brain barrier, along with rate of association
and dissociation to and from an antibody (Kosten and Owens 2005). These mechanistic
considerations are important because they reduce the behaviorally reinforcing effects since a large
component of reward is the euphoric “rush” experienced after initial drug administration.
Two types of immunotherapy have been established in preclinical studies concerning
abused drugs. Active immunization is a series of vaccinations of drug-protein conjugates to
stimulate the adaptive immune response and endogenous antibody production. These antibodies
circulate in the periphery and bind to drug molecules. An immunological memory is created by
the activation of memory B cells in response to re-exposure by booster shots and subsequent
amplification of initial response (Kosten et al. 2014). Passive immunization involves the
introduction of preformed antibodies produced in another animal immunized with the drug, and
immunoglobulins from serum samples are purified. Polyclonal antibodies are often generated from
multiple cell lines. Monoclonal antibodies (mAbs) are preferred for passive immunization because
these antibodies are derived from a single cell line and genetically identical to one another (Shorter
and Kosten 2011). Importantly, mAbs have exact functional and biochemical characteristics, such
as high affinity and specificity to the target drug and/or its active metabolites. These antibodies
can be custom-designed and dosing is precise unlike active immunization, which evokes a wide
variation of immune responses among individuals (Peterson and Owens 2009) especially if they
are immune-compromised at baseline. There are four types of mAbs which vary in efficacy of
antigen binding. Murine mAbs are 100% genetically derived from a mouse, whereas chimeric
mAbs are a combination of mouse (34%) and human (66%). Humanized mAbs are also a
combination of mouse (5-15%) and human (95-85%). Humanized mAbs are 100% human.
Chimeric and humanized monoclonal antibodies are often derived from a single cell line and
referred to as hybridoma cells since they contain a hybrid of human and murine genetic information
in the variable (Fv) region of the immunoglobulin G (IgG) protein. Hybridoma mAb cells are often
preferred for passive immunization because their high specificity for the immunological target
decreases the risk of cross-reactivity. Monoclonal antibodies are preferred in general though, since
introduction of foreign immunoglobulins with the polyclonal method can induce serum sickness
and transmission of animal viruses (Kosten and Owens 2005). An immunological memory is not
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created in comparison to active immunization, which requires repeated vaccinations. However, the
duration of action is much longer in monoclonal antibodies, offering immediate protection by
passive immunization.
The clinical objectives of immunotherapy against commonly abused drugs are gaining
recognition. These vaccinations are unlike immunizations against infectious agents because
intentions are shifted more toward therapeutic intervention rather than prophylaxis.
Immunotherapy may be used to treat acute and chronic overdose, reduce drug relapse, and decrease
the behaviorally reinforcing effects produced by drugs of abuse by attenuating neural reward
system activation. Effective treatments for drug addiction will likely be precipitated by further
research in this field, especially for those that do not have currently approved pharmacological
therapies but abuse is prevalent, i.e. cocaine (NIDA 2016). However, indications for drug
immunotherapy with prophylactic considerations are still meaningful. This method may be implied
to reach at-risk groups, including vulnerable adolescents and developing fetuses of drug-addicted
mothers (Kosten and Owens 2005). Immunotherapy for preventative application should be further
studied concerning immunological drug targets, which range from illicit (heroin) to legal
(nicotine).
Preclinical studies have reported promising results from early investigation in the 1970s
(Bonese et al 1974) to present day, encouraging drug immunotherapy research and evaluating its
efficacy by observing and measuring behavioral effects, self-administration paradigms, and
attenuated reward effects. Rats immunized with an anti-cocaine vaccine display reduced locomotor
effects and reinforcing behavior (Kosten and Owens 2005). A study done by Carrera et al. (2001)
reported evidence of the efficacy of active and passive immunotherapies for cocaine abuse and
evaluated locomotor activity and stereotypic behavior. The active immunotherapy employed a
second-generation cocaine immunoconjugate, GND, coupled with keyhole limpet hemocyanin
carrier protein (GND-KLH). The passive immunotherapy evaluated a murine anti-cocaine
monoclonal antibody comprised of another cocaine immunocongujate (GNC). The mAb used for
passive immunotherapy as a mechanistic comparison in this study is referred to as GNC92H2.
A baseline, pre-immunization level of locomotor activity was assessed in 32 male Wistar
rats in a 90-minute session after intraperitoneal injection of 15 mg/kg cocaine hydrochloride (HCl).
Active immunization of the rats was performed by a bolus injection administered intraperitoneally,
containing 250 μg of active protein-drug conjugate in saline at physiological pH. Since this
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immunization was active, two booster vaccinations were given at 21 and 35 days from initial
immunization to amplify antibody production. Passive immunizations were performed by a bolus
injection of 90 mg/kg mAb GNC92H2 in saline administered intravenously, through the tail vein.
Animals both actively and passively immunized were subjected to a 15 mg/kg cocaine challenge
administered intraperitoneally on the third, seventh, and twelfth day after the last booster (active,
GND-KLH) or after initial immunization (passive, GNC92H2), respectively. Both mechanisms of
immunotherapy displayed marked decreases in psychomotor effects of cocaine compared to the
control. Rats vaccinated with GND-KLH displayed a 76% reduction in locomotor activity
compared to baseline upon the first cocaine challenge, and a maximal 80% decrease from baseline
in locomotor activity in the last cocaine challenge. Passively immunized rats exposed to GNC92H2
(90 mg/kg) exhibited a 62% decrease from baseline in the first cocaine challenge. Of note, there
were also significant differences in stereotyped behavior between groups throughout the 90-minute
session, although similar behavioral suppression patterns were seen in both immunization groups.
Active immunization with GND-KLH prevented sensitization to cocaine, compared to the control
group which displayed increased locomotive and stereotypic behavior as a result of repeated
cocaine challenges (Carrera et al. 2001).
Since these findings have been reported, third-generation vaccines using viral gene transfer
vectors have been investigated. In a study by Wee et al. (2012) rats vaccinated with a thirdgeneration viral vector anti-cocaine vaccine exhibited decreased motivation to self-administer
cocaine when the progressive ratio requirement increased in a dose-response fashion compared to
control rats. Also in this study, non-vaccinated animals displayed extinction burst responding when
they received saline instead of cocaine upon self-administration, whereas vaccinated animals did
not. Cocaine-seeking mechanisms are attenuated or eliminated when antibodies are able to bind to
free cocaine molecules and prevent blood brain barrier crossing. One of the more recent cocaine
vaccines is TA-CD, which is a cocaine derivative coupled to inactivated cholera toxin B as a
functional carrier proteins. The antibodies produced by this vaccine are cocaine-specific, which
bind to the drug and break it down utilizing the mechanisms of cholinesterases to fragment the
active agent into inactive metabolites for excretion.
Immunotherapy for cocaine addiction has been rapidly developing and has recently made
it to clinical trials. A 24-week phase 2b, randomized, double-blind, placebo-controlled study
evaluated the efficacy of an active cocaine vaccination in 21 subjects. Vaccinated subjects
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produced high levels of IgG anti-cocaine antibodies, which significantly reduced cocaine use in
addicts. However, only 38% of subjects were able to maintain high levels of immunoglobulin
(Martell et al. 2009). This study was short, had a limited sample size, but offered some interesting
data that may contribute to the improvement of anti-cocaine vaccines. First, the quality and
efficacy of vaccines and boosters need to be improved to compensate for individual
pharmacogenomic differences in antibody production. Third generation vaccines are highly
complex, and perhaps future research should focus on the customizability of active immunization.
It has been reported in clinical studies that some subjects spontaneously produce low affinity anticocaine antibodies, which is likely due to pharmacogenomic variability (Kosten et al. 2014)
As with cocaine, there is no approved pharmacological treatment for methamphetamine
addiction (Chen et al. 2013). Methamphetamine is a difficult drug target for immunotherapy since
it is such a simple molecule, therefore greatly unnoticeable to the immune system in original form
(Julien et al. 2014). In rats, murine mAbs reduce brain exposure when methamphetamine is
administered intravenously. Self-administration was also decreased in immunized animals
compared to the control, and locomotor activity was greatly reduced (Chen et al. 2013). Three
doses of a passive mAb methamphetamine vaccine over a 53-day period produced antibodies in
rats, reducing drug distribution to the rat brain by over 60%, but did not attenuate locomotor effects
(Kosten and Owens 2005). Until 2012, only passive (mainly mAbs) immunizations for
methamphetamine abuse was studied and evaluated by serum concentration and behavioral effects
(locomotor activity, self-administration). Preclinical studies in the past five years investigating
active immunization with methamphetamine hapten complexes have reported that rats treated with
an active vaccine generate high serum-antibody concentrations with high binding affinity
(Montoya 2012).
Heroin has been considered an immunopharmacological target since the beginning of this
topic in drug treatment research. Bonese et al. (1974) reported decreased motivation to selfadminister morphine in rhesus monkeys immunized with morphine hapten conjugated with 6hemisuccinyl bovine serum albumin (BSA). More recent studies have confirmed that active
immunization of an anti-heroin vaccine eliminates self-administration (Stowe et al. 2012) In 2006,
Anton and Leff made a significant contribution to the study of drug abuse immunotherapy. They
developed a structural formation of a vaccine proven to be bivalent. In other words, the vaccine
had cross-reactivity for morphine and heroin. This is important because although immunotherapies
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are designed with high specificity, an opiate addict may try to override immunotherapy treatment
for oxycodone by using heroin if cravings are strong enough. Bivalent drug vaccines would be an
advance in immunotherapeutic technology because it can address a class of drugs rather than just
one specific drug. In rats immunized with the bivalent vaccine, significant levels of antibody
production with high affinity to morphine and heroin were observed (Anton and Leff 2006).
However, although heroin is an important therapeutic drug target, it is challenging to manufacture
an effective immunological defense since it has many psychoactive metabolites (Pravetoni et al.
2013).
Other commonly abused opiates have been studied as well. Pravetoni et al. (2013)
investigated oxycodone as an immunotherapeutic target. They immunized rats with oxycodone
haptens generated with tetraglycine or hemisuccinate linkers conjugated to BSA or KLH; these
rats produced high concentrations of antibodies to oxycodone and oxymorphone, an active
metabolite, with lower affinities to structurally similar opioids. To evaluate how much oxycodone
crossed the blood brain barrier to produce analgesia, this study tested the immunized animals’
response to thermal nociception. Immunization against oxycodone significantly reduced oxyinduced analgesia, providing evidence of the attenuation of central effects. This also supports the
theory behind immunization against drugs of abuse because by producing antibodies that bind to
oxycodone and oxymorphone, less drug is able to reach the brain, therefore analgesic effects are
weakened.
Nicotine has also been investigated in active and passive immunization, and has been
involved in clinical trials in addition to cocaine vaccines. Nicotine dependence is still highly
prevalent, and unlike most other drugs discussed here, it is legal in the United States. Although
smoking cessation programs and pharmacotherapies are available, 400,000 deaths occur annually
in the United States related to nicotine and smoking (Shorter and Kosten 2011). In rats, a series of
active immunization over 4-8 weeks induce antibody production that reduce nicotine distribution
to the brain by 40-60% (Kosten and Owens 2005). Importantly, clinically relevant single doses
and chronic doses have been studied. Also, it has been reported that in pregnant rats, nicotine
administration after immunization decreases fetal brain levels of nicotine, similar to maternal brain
levels. It has also been reported that vaccination decreases the ability of nicotine to alleviate
withdrawal (Kosten and Owens 2005). This is important because the physical need to avoid
withdrawal by compulsively taking drug is a component of addiction – if the drug can no longer
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relieve withdrawal, this diminishes the risk of relapse. NicVax and NicOb are vaccines for nicotine
abusers that have demonstrated significant results in clinical trials. NicVax has demonstrated a
favorable safety profile. In clinical trials, there was no observed increase in compensatory smoking
to overcome the effect of the vaccine. The treatment arm receiving the highest dose (200 μg)
showed significantly greater abstinence rates 30 days post-study completion (Shorter and Kosten
2011).
Although

there

are

many

benefits

to

advancing

the

development

of

immunopharmacotherapy, there are some modifications that need to be made before we can
wholeheartedly consider this as a viable treatment option for addiction. In the early 1970’s Bonese
et al. (1974) developed an early version of heroin immunotherapy. This group reported the effects
of an active immunization for heroin treatment, but the specificity of the antibody only recognized
heroin, which led to the concern that addicted individuals may just opt for another opiate of abuse
during vaccinations. This has been considered when developing second- and third-generation
immunotherapies. Another concern is that antibody production in response to active immunization
is widely variable among individuals in terms of amount produced and binding affinity to the drug
target. This may require further research into the customizability of active and passive
immunizations. For active immunization, frequent booster injections are necessary to maintain
circulating levels of anti-drug antibodies, typically in a one to six month series of injections. There
is a potential issue of compliance here, especially early in treatment when behavioral features of
addiction remain largely unchanged. The efficacy of the injection series is also affected by drugprotein conjugate quality, dosage, vaccination frequency, and individual variability in response,
i.e. antibody production. Another complication with active immunizations is that it will not be a
viable treatment option in addicted individuals with immune deficiencies. This is especially
important because human immunodeficiency virus (HIV) is prevalent in drug users that abuse
heroin and other drugs administered intravenously. Passive immunotherapy would be the next
option, but antibodies generated in another animal and then its immunoglobulins transferred via
purified serum still run the risk of transmitting animal viruses and serum sickness. Monoclonal
antibodies are usually the preferred option for passive immunotherapies, and they are expensive
to produce (Kosten and Owens 2005).
Active and passive immunotherapies against drugs of abuse have shown promising results
in animal models of addiction, and clinical trials where applicable. This treatment option is rapidly
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developing with an increase in focus for application in acute and chronic overdose (passive
immunization only), reduction in drug relapse, and prophylactic uses for at-risk populations
(Kosten and Owens 2005). Drug abuse is rampant, with damaging impacts on society and the
economy. Ideally, the development of prophylactic immunotherapies for drug abuse should be
further studied to reach at-risk youth born to drug-addicted parents or living in urban areas of low
socioeconomic status, where drugs are a central and dangerous theme. Perhaps by breaking the
cycle of addiction by preventative immunization, illicit drugs would no longer produce reinforcing
effects that lead to abuse and addiction, which may be beneficial against fighting the war on drugs,
which often seeps into areas of poverty.
There will most likely be future developments in immunotherapy treatment in the direction
of advancing adjuvants with greater emphasis on antibody-mediated immunity rather than cell
mediated immunity (Alving et al. 2014). The addition of adjuvant agents to basic vaccines may
include the introduction of cytokines and other molecules to enhance immune response (Kosten
and Owens 2005). Biologic approaches, such as enzyme-based therapies in addition to antibodies
and vaccines need to be modified so that individual systems provoke the appropriate immune
response with sufficient levels of immunoglobulin production to block drugs (Montoya 2012).
Delivery systems may have to be improved as well – perhaps instead of a series of injections for
active immunity, a formulation can be created in sustained release form to sustain antibody levels
(Kosten and Owens 2005). This development would eliminate the risk of non-compliance in active
immunization, since it would be a reformulated single dose. Advances in bivalent vaccines, as
described in Anton and Leff (2006), would contribute to the progression of immunotherapy.
Immunotherapy is not the end-all, be-all for treating drug addiction although animal models and
clinical trials have displayed encouraging data. In fact, if future developments increase this
treatment’s efficacy for clinical use, it should be an option for drug-addicted patients in
combination with behavioral therapy and other necessary pharmacotherapies. Hopefully, this
technology will progress and eventually extend to treating addiction to other drugs of abuse not
mentioned here, such as ecstasy and other designer drugs.
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